Complex Hereditary Spastic Paraplegia (HSP): Comprehensive Research Report

1. Disease Information

Overview. Hereditary spastic paraplegia (HSP) is not a single disease but a large, clinically and genetically heterogeneous group of inherited neurodegenerative disorders whose unifying pathological feature is retrograde ("dying-back"), length-dependent axonal degeneration of the corticospinal tracts (and often the dorsal columns), producing progressive lower-limb spasticity and weakness (MedLink Neurology; PMC6827077). HSPs are clinically split into: - Pure (uncomplicated) HSP — progressive spastic paraplegia with hyperreflexia, extensor plantar responses (Babinski sign), and urinary urgency/bladder dysfunction as essentially the only findings (GeneReviews NBK1509). - Complex (complicated) HSP — spastic paraplegia plus additional neurological features (ataxia, peripheral neuropathy, epilepsy, intellectual disability/cognitive decline, extrapyramidal signs/parkinsonism, optic atrophy, retinopathy, deafness) and/or non-neurological systemic features (dysmorphism, skeletal deformity, skin changes) (PMC4939695; PMC8749458).

More than 88 spastic paraplegia (SPG) gene loci have been described, with 40+ confirmed causal genes, spanning autosomal dominant (AD), autosomal recessive (AR), X-linked, and (rarely) mitochondrial inheritance (PMC8662366; Pharos disease page). Complex forms are disproportionately autosomal recessive, with SPG11 (spatacsin), SPG15/ZFYVE26 (spastizin), SPG7 (paraplegin), SPG5A/CYP7B1, SPG35/FA2H, SPG20 (Troyer syndrome), and the AP-4 complex disorders (SPG47/50/51/52) among the most frequent/best characterized complex etiologies.

Key identifiers. - Pharos lists "complex hereditary spastic paraplegia" as a distinct disease-concept entry (Pharos). - There is no single unifying MONDO/OMIM ID for "complex HSP" as a category — it is a cross-cutting clinical descriptor applied across dozens of individually MONDO/OMIM-coded SPG subtypes. Representative examples: pure-or-complex AD spastic paraplegia group MONDO:0008438; AR complex spastic paraplegia (SPG23) MONDO:0010046; pure-or-complex AR spastic paraplegia (SPG48) MONDO:0013342 (search aggregation). - Individual OMIM entries exist per subtype, e.g., SPG3A OMIM #182600, SPG5A OMIM #270800, SPG7 OMIM #607259, SPG12 OMIM #604805 (OMIM). - Orphanet groups HSP under ORPHA:99013 ("Hereditary spastic paraplegia"), with individual ORPHA codes per numbered SPG subtype and clinical form (pure vs. complicated). - ICD-10: G11.4 (hereditary spastic paraplegia); ICD-11: 8A02.1. - MeSH: D015419 (Spastic Paraplegia, Hereditary).

Synonyms: Familial spastic paraplegia; Strümpell-Lorrain disease/syndrome; hereditary spastic paraparesis; French settlement disease (historical); "complicated"/"complex" HSP.

Evidence base: Predominantly aggregated disease-level literature (case series, natural-history cohorts, genetic-diagnostic cohorts) rather than large-scale EHR studies, though a few population-based epidemiologic studies exist (Norway, England/Northern Ireland; see Section 9) (PMC12210554).

2. Etiology

Primary cause: Monogenic — pathogenic variants in one of >88 SPG loci disrupting core cell-biological processes in long CNS axons (see Section 6). Genetic architecture, not environmental exposure, is the dominant causal factor; complex forms are enriched for AR inheritance and biallelic loss-of-function alleles.

Genetic risk factors: - Causal, highly penetrant variants in SPAST (SPG4), ATL1 (SPG3A), REEP1 (SPG31) account for pure HSP; SPAST/ATL1/REEP1 together account for well over 50% of all HSP (JCI PMC2846052). - Complex/recessive HSP causal genes: SPG11 (spatacsin) — most prevalent AR complex HSP gene (~8% of registered AR HSP cases) (Frontiers/PMC search synthesis); SPG15/ZFYVE26; SPG7 (paraplegin); CYP7B1 (SPG5A); FA2H (SPG35); SPG20 (spartin, Troyer syndrome); AP4B1/AP4M1/AP4E1/AP4S1 (SPG47/50/51/52). - Consanguinity is a strong risk-enrichment factor for AR complex HSP, particularly in Mediterranean and Middle Eastern populations with high consanguinity rates (PMC8944001). - Modifier genes/digenic inheritance: recent work reports digenic SPG7/AFG3L2 interactions modulating motor neuron and cerebellar phenotypes (medRxiv preprint, 2025) (medRxiv).

Environmental/risk modifiers: No established environmental or infectious causal contributors; age at onset and severity are influenced by genotype (see Section 8) rather than known exposures. No consistent sex-ratio skew has been reported ("no differences in rate relating to gender were found") (PMC8944001).

Protective factors: None well established at the population level; some evidence that later disease onset in certain genotypes (e.g., SPG3A vs. SPG4) correlates with slower progression, which may reflect allelic/genetic background effects rather than a true protective factor (Springer natural history).

Gene-environment interaction: Not a major feature of this disease group; HSP is considered predominantly monogenic with modifier-gene (not environmental) modulation of expressivity.

3. Phenotypes

Core "pure" phenotype (present in virtually all HSP, complex or pure)

Frequencies above from a large SPG4/SPAST-HSP cohort (Neurology Genetics NXG.0000000000000664).

Complex-form additional phenotypes (by representative subtype)

Age of onset / progression / severity: Highly variable — from congenital/infantile (AP-4-HSP) to childhood (SPG11, SPG35) to adult/late-onset (SPG4, SPG7, SPG3A), with mean HSP onset age around 24 years across pooled cohorts (PMC8944001). Complex forms tend to progress faster than pure forms: Spastic Paraplegia Rating Scale (SPRS) annual progression ~1.3 points/year in complicated HSP vs. 0.6 points/year in pure HSP (Austrian natural history cohort, Springer 2025). Disease severity/progression is genotype-dependent: SPG11 carries the highest severity burden; SPG3A tends to progress more slowly than SPG4 (same source).

Quality of life: Direct QoL instrument data specific to HSP is sparse in the literature surveyed; management studies report substantial impact on mobility/independent ambulation and increased psychiatric comorbidity (anxiety/depression) documented in the England/N. Ireland epidemiologic cohort (PMC12210554).

4. Genetic/Molecular Information

Causal genes (selected, complex-form-relevant): | Gene | HGNC | Locus/OMIM | Protein | Inheritance | |---|---|---|---|---| | SPAST | HGNC:11233 | SPG4, OMIM #182601 | Spastin (microtubule-severing AAA-ATPase) | AD | | ATL1 | HGNC:30288 | SPG3A, OMIM #182600 | Atlastin-1 (ER-shaping GTPase) | AD | | REEP1 | HGNC:13703 | SPG31 | REEP1 (ER-shaping hairpin protein) | AD | | SPG11 | HGNC:11226 | SPG11, OMIM #604360 | Spatacsin | AR | | ZFYVE26 | HGNC:29128 | SPG15 | Spastizin | AR | | SPG7 | HGNC:11237 | SPG7, OMIM #607259 | Paraplegin (m-AAA mitochondrial protease subunit) | AR (occasionally digenic w/ AFG3L2) | | CYP7B1 | HGNC:2652 | SPG5A, OMIM #270800 | Oxysterol 7α-hydroxylase | AR | | FA2H | HGNC:20139 | SPG35 | Fatty acid 2-hydroxylase | AR | | SPART (SPG20) | HGNC:11227 | SPG20 (Troyer syndrome) | Spartin | AR | | AP4B1 | HGNC:567 | SPG47 | AP-4 complex β subunit | AR | | AP4M1 | HGNC:569 | SPG50 | AP-4 complex μ subunit | AR | | AP4E1 | HGNC:568 | SPG51 | AP-4 complex ε subunit | AR | | AP4S1 | HGNC:571 | SPG52 | AP-4 complex σ subunit | AR |

Pathogenic variant types: Loss-of-function (nonsense, frameshift, splice-site) predominates in AR complex forms (e.g., SPG11, SPG20, AP-4 genes are essentially null alleles: "the pathogenesis of Troyer syndrome results from a loss-of-function mechanism" rather than a toxic truncated protein) (Wikipedia SPG20 synthesis). Missense variants with dominant-negative or haploinsufficient effects predominate in AD pure forms (SPAST, ATL1). Variant classification should follow ACMG/AMP criteria via ClinVar/ClinGen; allele frequencies for pathogenic variants are characteristically rare/absent in gnomAD, consistent with a rare Mendelian disease, though specific founder alleles exist in consanguineous/isolate populations.

Functional consequences: - Spastin: loss of microtubule-severing activity → disrupted axonal microtubule dynamics/transport. - Atlastin-1/REEP1: loss of ER tubule-fusion/shaping activity, disrupting the tubular ER network's coordination with microtubules in long axons (PMC2846052). - Spatacsin/spastizin (SPG11/SPG15): loss of AP-5-adaptor accessory function → defective lysosomal reformation/tubulation and autophagosome-lysosome fusion, causing autophagosome/enlarged-lysosome accumulation (PMC4078876). - Paraplegin (SPG7): loss of m-AAA mitochondrial protease function → mitochondrial proteostasis failure, permeability-transition-pore dysregulation, ATPase deficiency (Lancet eBioMedicine). - CYP7B1: loss of oxysterol 7α-hydroxylase activity → toxic accumulation of 25- and 27-hydroxycholesterol, which are neurotoxic and blood-brain-barrier permeable (ScienceDirect; PubMed 18252231). - AP-4 complex subunits: loss of AP-4-mediated vesicular sorting (notably ATG9A trafficking) → autophagy-initiation defects; Ap4b1-knockout mice show "ATG9A mislocalization" (PMC9825813).

Modifier genes: AFG3L2 as a digenic modifier/co-causal partner with SPG7 in some motor neuron/cerebellar presentations (medRxiv 2025).

Epigenetics/chromosomal abnormalities: Not a prominent feature of HSP pathogenesis in the literature surveyed; disease is driven by point/small indel variants in nuclear-encoded genes rather than large chromosomal rearrangements or a described episignature.

5. Environmental Information

No specific toxin, infectious agent, or lifestyle exposure has been causally linked to HSP; the searched literature identifies HSP as a purely genetic disease group. Environmental/behavioral factors have not been studied as HSP risk modifiers in the sources reviewed. This section is largely not applicable for this Mendelian disease class beyond noting that catabolic stress or intercurrent illness is not a described trigger (in contrast to some other neurogenetic disease classes in this KB, e.g., metabolic intoxication disorders).

6. Mechanism / Pathophysiology

Core convergent pathophysiology: Regardless of causal gene, HSP mechanistically converges on length-dependent ("dying-back") retrograde axonal degeneration of the corticospinal tract (and often dorsal columns), because these are the longest axons in the human CNS (up to ~1 m) and are maximally dependent on efficient long-range organelle/cargo transport and membrane maintenance (PMC6827077). "The central nervous system's long axons are hotspots and the first site of hereditary spastic paraplegia axonopathy."

Major convergent molecular pathway clusters (from PMC8004882 and PMC6031053):

1. ER shaping / membrane trafficking (SPAST, ATL1, REEP1 axis). Atlastin-1 (a GTPase) mediates homotypic fusion of ER tubules to form three-way junctions of the tubular ER network; it physically interacts with spastin (microtubule-severing AAA-ATPase) and REEP1 (a hairpin ER-shaping protein), and this tripartite complex "coordinate[s] microtubule interactions with the tubular ER network" specifically within long corticospinal axons (JCI, PubMed 20200447). Loss of any one component destabilizes ER-microtubule coupling, impairing axonal ER distribution and organelle transport.
2. Lysosomal/autophagosome maturation (SPG11/SPG15 axis). Spatacsin (SPG11) and spastizin (SPG15) form a complex, cooperating with the AP-5 adaptor complex in late-endosome/lysosome membrane sorting; loss of function causes defective autophagosome-to-lysosome fusion, lysosome depletion, and enlarged/dysfunctional lysosomes, driving neurodegeneration with the distinctive thin-corpus-callosum, cognitive, and retinal phenotype (PMC4078876; PMC4540459). A 2024 zebrafish spastizin model additionally shows axon demyelination and degeneration, implicating oligodendrocyte/myelin dysfunction as a downstream mechanism (bioRxiv/PMC11539067).
3. Mitochondrial quality control (SPG7 axis). Paraplegin, part of the mitochondrial inner-membrane m-AAA protease, is required for mitochondrial protein quality control and ribosome assembly; its loss causes ATPase deficiency, impaired permeability-transition-pore "flickering," and secondary anterograde/retrograde axonal transport failure, producing progressive distal axonopathy of spinal and peripheral nerves that faithfully recapitulates the human SPG7 phenotype in Spg7-knockout mice (Lancet eBioMedicine).
4. Cholesterol/oxysterol metabolism (CYP7B1/SPG5A axis). Loss of oxysterol 7α-hydroxylase blocks the alternative bile-acid synthesis pathway, causing toxic accumulation of 25- and 27-hydroxycholesterol, which cross the blood-brain barrier and are directly neurotoxic to corticospinal and dorsal-column axons (ScienceDirect).
5. Complex sphingolipid/myelin lipid metabolism (FA2H/SPG35 axis). Loss of fatty acid 2-hydroxylase impairs synthesis of 2-hydroxylated sphingolipids required for normal myelin composition, producing a leukodystrophy-like phenotype with white-matter abnormalities, sometimes overlapping neurodegeneration with brain iron accumulation (the entity is also called fatty acid hydroxylase-associated neurodegeneration, FAHN) (PMC6238570; PubMed 38353247).
6. AP-4 vesicular sorting (SPG47/50/51/52 axis). Loss of any AP-4 complex subunit disrupts anterograde sorting of ATG9A (an autophagy-initiation transmembrane protein) from the trans-Golgi network, impairing autophagosome biogenesis; Ap4b1-knockout mice show motor dysfunction, aberrant brain morphology, and ATG9A mislocalization, closely mirroring the profound infantile/childhood-onset human phenotype (PMC9825813).
7. Non-cell-autonomous glial mechanism. Emerging evidence (in vitro/model organism) implicates impaired lipid/cholesterol homeostasis in astrocytes as a non-cell-autonomous driver of cortical projection-neuron degeneration in HSP, expanding the mechanism beyond a purely neuron-intrinsic model (PMC7720406).
8. Lipid metabolism broadly. A dedicated review ("Lipids in the Physiopathology of Hereditary Spastic Paraplegias") frames disrupted lipid/membrane metabolism (cholesterol, sphingolipids, phospholipids) as a unifying downstream theme across many complex-HSP genes (PMC7059351).

Suggested GO terms: GO:0007018 (microtubule-based movement), GO:0016183 (ER tubular network organization), GO:0007009 (plasma membrane organization) → more precisely GO:0071786 (ER tubular network organization), GO:0006914 (autophagy), GO:0007009, GO:1902774 (late endosome to lysosome transport), GO:0007005 (mitochondrion organization), GO:0034599 (cellular response to oxidative stress), GO:0008203 (cholesterol metabolic process), GO:0030149 (sphingolipid catabolic process), GO:0007041 (lysosomal transport).

Suggested CL terms: CL:0000029 (corticospinal tract upper motor neuron)/CL:0011005 (corticospinal neuron), CL:0000030 (glutamatergic neuron, alt.), CL:0000127 (astrocyte, for the non-cell-autonomous glial mechanism), CL:0000128 (oligodendrocyte, for SPG15 demyelination).

Causal chain summary (generalized template for a complex-HSP disorder node): Gene-specific lesion (e.g., biallelic SPG11 loss-of-function) → organelle-specific dysfunction (lysosomal/autophagic dysfunction) → impaired long-axon maintenance (corticospinal + additional tract/structure involvement, e.g., corpus callosum, cerebellum, retina) → length-dependent retrograde axonal degeneration → progressive spasticity plus complex-form-specific extra-pyramidal features (cognitive decline, ataxia, retinopathy, etc.).

7. Anatomical Structures Affected

Organ/system level: - Primary: central nervous system — corticospinal tracts (upper motor neuron), often dorsal (posterior) spinal columns. - Secondary (complex forms): cerebellum (ataxia), corpus callosum (SPG11/15 thinning), peripheral nerves (neuropathy — SPG7, AP-4 disorders), optic nerve (atrophy — SPG7), retina (pigmentary retinopathy — SPG11/15), lens (cataracts — SPG11/15), skeletal system (pes cavus, scoliosis, short stature — SPG20), bladder (neurogenic bladder/urgency), white matter broadly (leukodystrophy — SPG35).

Tissue/cell level (Cell Ontology): - CL:0011005 corticospinal neuron / CL:0000029 (upper motor neuron parent term via UBERON:0002240 spinal cord) - CL:0000127 astrocyte (non-cell-autonomous mechanism) - CL:0000128 oligodendrocyte (myelin/demyelination component) - CL:0000540 neuron (general) - Retinal photoreceptor cells (SPG11/15 retinopathy) - Peripheral sensory/motor neurons (SPG7, AP-4 neuropathy)

Subcellular level (GO Cellular Component): - GO:0005783 endoplasmic reticulum (tubular ER; SPAST/ATL1/REEP1) - GO:0005739 mitochondrion, specifically GO:0005743 mitochondrial inner membrane (SPG7 m-AAA protease) - GO:0005764 lysosome / GO:0005776 autophagosome (SPG11/SPG15, AP-4) - GO:0005874 microtubule / GO:0015630 microtubule cytoskeleton - GO:0030134 COPII-coated ER-to-Golgi transport vesicle (AP-4-related Golgi sorting)

Localization (UBERON): - UBERON:0002240 (spinal cord), UBERON:0001133 (corticospinal tract), UBERON:0002756 (corpus callosum), UBERON:0002037 (cerebellum), UBERON:0000966 (retina), UBERON:0000970 (eye), UBERON:0001021 (nerve/peripheral nervous system). - Lateralization: HSP motor findings are typically bilateral and symmetric (a distinguishing feature from unilateral corticospinal lesions of other etiologies).

8. Temporal Development

Onset: Ranges continuously from congenital/infantile (AP-4-HSP: global developmental delay from infancy) through childhood (SPG11 median onset in the first two decades; SPG35 childhood-onset with seizures/leukodystrophy) to adult-onset (SPG4, SPG7 — onset can occur "as late as age 72 years" for SPG7) (PMC8793673). Mean HSP onset across pooled cohorts ≈ 24 years (PMC8944001). SPG5A median onset ~13 years (range 1–63) (Elsevier).

Onset pattern: Insidious/chronic-progressive in essentially all forms; not acute or episodic.

Progression: - Generally slow but genotype-dependent; overall SPRS progression ~0.9 points/year pooled, but 1.3 points/year in complicated HSP vs. 0.6 points/year in pure HSP (Springer 2025). - SPG11 carries higher severity and a more rapid course, with "limited lifespan of 3 to 4 decades after disease-onset" reported in some cohorts and rapid deterioration described in Dutch SPG11 cohorts (PMC3798836). - Loss of independent ambulation: variable — from within 1–2 decades of onset to intact ambulation after 24 years in milder genotypes; later age at onset is paradoxically associated with faster loss of independent walking in some analyses. - SPG3A tends to progress more slowly than SPG4. - AP-4-HSP: children who achieve independent walking typically lose this ability months to a few years later as hypotonia converts to hypertonia/spasticity (Boston Children's Hospital).

Disease course pattern: Chronic, progressive, non-remitting (not relapsing-remitting or episodic). No spontaneous-remission pattern is described.

Critical periods: For the AP-4 disorders and other infantile-onset complex forms, early diagnosis is critical because gene-therapy intervention windows are being defined pre-symptomatically or in very early disease (see Section 12) — the SPG50 trial specifically dosed a pre-symptomatic 5-month-old alongside symptomatic children to test whether earlier intervention alters outcome (CGTlive).

9. Inheritance and Population

Epidemiology: - Pooled global HSP prevalence estimates: 2–7.4/100,000 across most populations, with a range of 0.1–9.6/100,000 reported worldwide and modeling estimates converging around 3.6/100,000 overall (PMC8944001). - Genotype-specific global prevalence estimates: SPG4 ≈ 0.90/100,000; SPG7 ≈ 0.22/100,000; SPG11 ≈ 0.34/100,000; SPG15 ≈ 0.13/100,000 (BMC Neurology, Springer). - Norway (population >2.5M): prevalence 7.4/100,000 (2009 study) — among the highest reported. - Spain: ~2.24/100,000 (lower). - Higher prevalence reported in Mediterranean/Middle Eastern populations with high consanguinity. - Incidence in England/Northern Ireland rose from 0.12/100,000 person-years (2000) to 0.29/100,000 person-years (2021) (PMC12210554) — likely reflecting improved genetic diagnosis rather than true incidence increase.

Inheritance pattern: All classical Mendelian modes reported — AD (SPG3A, SPG4, SPG31, SPG12), AR (SPG5A, SPG7, SPG11, SPG15, SPG20, SPG35, AP-4 disorders SPG47/50/51/52), X-linked (e.g., SPG1/L1CAM, SPG2/PLP1), and rare mitochondrial-associated presentations.

Penetrance/expressivity: AD forms (SPAST, ATL1) show high but sometimes age-dependent penetrance and marked intra-familial variable expressivity (age of onset and severity can differ substantially between relatives carrying the same variant). AR complex forms are generally fully penetrant when biallelic loss-of-function variants are present, given the severe cellular consequences (e.g., near-complete loss of AP-4 complex function).

Genetic anticipation: Not a characteristic feature of HSP (unlike repeat-expansion disorders); HSP genes are not repeat-expansion loci in the mainstream classification.

Consanguinity: A major risk-enrichment factor for AR complex HSP; complex AR forms are relatively more frequent in populations/regions with high consanguinity rates.

Founder effects: Population-specific founder alleles have been described for several SPG genes in isolated/consanguineous populations (implicit in the geographic prevalence variation, though the sources reviewed did not enumerate specific founder variants in detail).

Population demographics: No described sex-ratio skew; age at onset varies as above by genotype; geographic distribution shows Mediterranean/Middle Eastern enrichment for consanguinity-associated AR complex subtypes and higher Norwegian/Northern European prevalence for AD pure forms.

10. Diagnostics

Clinical exam/tests: - Neurological exam: lower-limb spasticity, hyperreflexia, Babinski sign, clonus, pes cavus. - MRI brain/spine: thin corpus callosum (SPG11/15 — a key distinguishing neuroimaging clue), white-matter/leukodystrophic changes (SPG35), cerebellar atrophy (SPG7), "ears of the lynx" sign (classically associated with SPG11/15 thin corpus callosum + periventricular white matter changes). - Ophthalmologic exam: optic disc pallor/atrophy (SPG7), retinal pigmentary changes (SPG11/15), cataract exam. - Nerve conduction studies/EMG: to detect peripheral neuropathy component in complex forms (SPG7, AP-4 disorders). - Urodynamic studies for neurogenic bladder assessment. - Biochemical: elevated serum/CSF 25- and 27-hydroxycholesterol as a diagnostic/monitoring biomarker specific to SPG5A/CYP7B1 (ScienceDirect).

Genetic testing: - Recommended approach: Given >90 implicated genes, next-generation sequencing gene panels are the recommended cost-effective first-line test; a representative panel (SpastiSure3.0) covers 118 HSP-associated genes. - Diagnostic yield: Overall genetic diagnosis achieved in ~29–31% of clinically suspected pediatric HSP cohorts using panel testing; yield rises with age-stratified analysis (up to 37% in ages 0–5 when panel is followed by exome) (Human Genomics, Springer). Diagnostic rate is markedly inheritance-pattern-dependent: 56.7% in AD HSP, 55.5% in AR HSP, but only 21.2% in sporadic HSP cases, and overall diagnostic gap of ~25% remains even in the best-studied cohorts. - Whole exome sequencing (WES): Recommended when panel testing is negative, particularly for complicated/complex phenotypes; "exome sequencing is a useful diagnostic tool for complicated forms of hereditary spastic paraplegia" (PubMed 23438842); WES clearly benefits children with suspected HSP when panels are non-diagnostic (PMC13040777). - Chromosomal microarray/karyotype: not first-line, as HSP is overwhelmingly a single-gene/small-variant disease rather than a copy-number/structural disorder, though CNV analysis is sometimes included in comprehensive panels.

Clinical diagnostic criteria: No single formal DSM/ICD-based criteria set beyond the clinical pure-vs-complex classification described above; diagnosis rests on clinical phenotype plus molecular confirmation, given marked genetic heterogeneity and phenocopy overlap with other upper-motor-neuron disorders (differential diagnosis includes primary lateral sclerosis, multiple sclerosis, dopa-responsive dystonia, cerebral palsy [static, non-progressive — a key distinguishing feature], vitamin B12/E deficiency, and adrenomyeloneuropathy).

Screening: No population-based newborn or carrier screening program specific to HSP; genetic counseling and cascade testing are recommended in families with a known pathogenic variant, particularly for AR complex forms in consanguineous families.

11. Outcome/Prognosis

Survival/mortality: HSP itself is not typically directly life-limiting in pure/adult-onset forms; however, severe complex forms (notably SPG11) are associated with reduced functional lifespan — "limited lifespan of 3 to 4 decades after disease-onset" in some SPG11 cohorts — reflecting cumulative disability and complications rather than the spasticity itself being acutely fatal ([derived from natural history literature above]).

Morbidity/function: - Progressive loss of independent ambulation is the dominant functional endpoint; timing is highly genotype-dependent (see Section 8). - SPRS (Spastic Paraplegia Rating Scale) is the standard longitudinal functional/severity outcome measure, with annual progression rates of ~0.6 (pure) to ~1.3 (complicated) points/year. - Complex-form comorbidities (cognitive decline, ataxia, visual impairment from retinopathy/optic atrophy, neurogenic bladder, orthopedic deformity) compound disability beyond the pure motor phenotype. - Increased burden of common mental health outcomes (anxiety, depression) documented in a large England/Northern Ireland epidemiologic cohort of HSP patients (PMC12210554).

Complications: Contractures, scoliosis/orthopedic deformity, neurogenic bladder/urinary tract complications, falls/fractures from gait instability, and (in complex forms) seizures, visual impairment, and cognitive decline.

Recovery potential: No spontaneous recovery; disease-modifying interventions are only now emerging (gene therapy — Section 12) and remain investigational/single-patient/early-phase.

Prognostic factors: Genotype is the dominant prognostic factor (SPG11 = more severe/faster; SPG3A = slower than SPG4); age at onset; presence of complex-form features generally predicts faster SPRS progression than pure HSP.

12. Treatment

Current standard of care: There is no disease-modifying therapy approved for the great majority of HSP subtypes; management is symptomatic and multidisciplinary ("symptomatic management should be multidisciplinary to achieve better control of motor symptoms... and prevent skeletal deformities") (Merck Manual; PMC10858081).

Pharmacotherapy (symptomatic): - Antispastic agents: baclofen (first-line), tizanidine, diazepam, clonazepam, dantrolene — MAXO/NCIT: NCIT:C15986 Pharmacotherapy, with therapeutic_agent CHEBI baclofen (CHEBI:2942), tizanidine. - Botulinum toxin type A/B (BTX-A/BTX-B) — intramuscular injection for focal spasticity; reduces spasticity and fatigue without affecting depression/excessive daytime sleepiness; combined BTX + intensive physiotherapy shows added benefit (PMC7046620; recent comprehensive 2025 review, PMC12567745). MAXO/NCIT: could map to NCIT:C1198 (Botulinum Toxin) as therapeutic_agent under Pharmacotherapy. - Oxybutynin for urinary urgency/neurogenic bladder. - Historical clinical-trial pharmacologic agents (mostly negative or inconclusive for disease modification): atorvastatin, gabapentin, L-threonine, dalfampridine (4-aminopyridine), methylphenidate (PMC9321931). - SPG5A/CYP7B1-specific: atorvastatin + chenodeoxycholic acid (± resveratrol) trialed to normalize elevated 25-/27-hydroxycholesterol and restore bile-acid profile; a randomized controlled trial (Schöls et al., Brain 2017, PMID 29126212) found atorvastatin reduced serum 27-OHC/25-OHC (though CSF 27-OHC reduction was not significant) (PubMed 29126212).

Advanced/gene-targeted therapeutics (investigational, complex-HSP-specific): - SPG50 (AP4M1) gene therapy: Intrathecal AAV9/AP4M1 gene replacement. A single-patient phase 1 trial (NCT06069687) dosed a 4-year-old boy intrathecally with 1×10¹⁵ vg AAV9-AP4M1 in March 2022 — among the largest AAV9 CSF doses ever given — with 12-month follow-up showing apparent disease-course stabilization and no serious adverse events (Nature Medicine 2024, PMC11271397). Elpida Therapeutics' "Melpida" program (NCT05518188, Phase I/II) has since dosed additional participants (ages 3–5 years at 1×10�1⁵ vg; a pre-symptomatic 5-month-old at 4×10¹⁴ vg), with FDA clearance to proceed to a Phase III trial (8 children, initiated August 2024) (Clinical Trials Arena; CGTlive). Preclinical AAV9/AP4M1 work established safety/efficacy in mouse models first (PMC10178841). - SPG47 (AP4B1) gene therapy: Preclinical AAV9-hAP4B1 delivered into the cisterna magna in a mouse model, with "restoration of various hallmarks of disease" (PMC11554807); patient-advocacy-driven programs coordinated via Cure AP-4/Cure SPG47 foundations. - SPG5 (CYP7B1) gene therapy: AAV8-based gene-replacement therapy in preclinical development (PMC12309954); an mRNA-based therapeutic strategy for SPG5 has also been proposed (Molecular Therapy Methods & Clinical Development, Cell.com). - Modality classification: therapeutic_modality: GENE_THERAPY for the AAV programs above (AAV9/AAV8 capsid, intrathecal or intra-cisterna-magna delivery, gene-replacement mechanism — not gene editing).

Surgical/interventional: Orthopedic surgery for severe contractures/scoliosis; intrathecal baclofen pump for refractory severe spasticity; selective dorsal rhizotomy considered in select cases (extrapolated from general spasticity-management literature, not HSP-specific data in the sources reviewed).

Supportive/rehabilitative: - Physical therapy/exercise: maintains mobility, muscle strength, range of motion, reduces fatigue and spasms (MAXO:0000011 physical therapy) — non-pharmacological systematic review (2023) supports benefit (PMC10858081; Springer). - Occupational therapy, orthotics (ankle-foot orthoses for foot drop/pes cavus), gait aids/wheelchairs as disease progresses. - Emerging modality: radial extracorporeal shock wave therapy reported efficacious in an HSP case report (PMC12338253).

Experimental (clinical trials): Natural history/biomarker studies (NCT02859428 for SPG3A/SPG4/SPG31; SPG5 natural history/RCT [PubMed 29126212]); NCT04712812 registry/natural history study for early-onset HSP; the SPG50 gene-therapy trials above.

Treatment strategy: No formal disease-specific treatment algorithm exists analogous to oncology guidelines; management is individualized/multidisciplinary (neurology, physiatry/rehabilitation, urology, orthopedics, ophthalmology for complex forms, genetics/genetic counseling). Personalized/genotype-guided approaches are emerging specifically for SPG5A (biochemical-pathway-targeted therapy) and the AP-4 disorders/SPG50 (gene replacement).

13. Prevention

Primary prevention: Not applicable in the traditional sense (no modifiable risk-factor exposure to eliminate); the only "primary prevention" avenue is reproductive risk reduction via genetic counseling, carrier screening, and preimplantation genetic diagnosis (PGD) in families with a known pathogenic variant, particularly relevant for AR complex forms in consanguineous unions.

Secondary prevention: Early molecular diagnosis (panel/WES) to enable early initiation of symptomatic/supportive management and, increasingly, eligibility screening for investigational gene therapy (the SPG50 program explicitly enrolled a pre-symptomatic infant to test whether earlier intervention alters the trajectory).

Tertiary prevention: Prevention of secondary complications — regular physical therapy/stretching to prevent contractures, orthopedic surveillance for scoliosis, urological surveillance for bladder complications, ophthalmologic monitoring in complex forms with retinal/optic involvement.

Genetic counseling: Central to management in families with identified variants — risk assessment for future pregnancies, cascade testing of at-risk relatives, and discussion of reproductive options (PGD, prenatal testing) given the autosomal recessive predominance of complex HSP and the consanguinity risk factor.

Public health/behavioral/immunization/prophylaxis: Not applicable — no described environmental, infectious, or vaccine-preventable component to this disease group.

14. Other Species / Natural Disease

The literature reviewed focused on induced/engineered models (Section 15) rather than naturally occurring veterinary HSP. No spontaneous naturally-occurring canine/feline/equine HSP orthologous disease was identified in the sources searched (unlike some other neurogenetic disorders with well-documented veterinary natural disease counterparts). This section is likely not well populated for this disease from available searches; a targeted OMIA search would be needed to confirm whether any spontaneous animal spastic paraplegia orthologs are catalogued (not performed here due to no hits surfacing in general search).

Orthologous genes (NCBI Gene, for model-organism cross-reference): Spast (mouse Gene ID: 232265), Atl1 (mouse), Spg7 (mouse Gene ID: 105875), Ap4b1 (mouse), Ap4m1 (mouse), Spg20/Spart (mouse) — all with characterized knockout mouse models (below).

15. Model Organisms

Mouse models (most extensively characterized): - Spg7−/− (paraplegin-null) mouse: Progressive motor impairment from ~4.5 months of age; retrograde axonal degeneration of long descending (corticospinal) and ascending (dorsal column) spinal tracts plus peripheral and optic nerves; early appearance of ultrastructurally abnormal mitochondria in affected axons, worsening with age. Explicitly stated to "successfully recapitulate the key phenotypic and pathological features observed in SPG7 patients" (PMC5628248 synthesis; PMC7469654). - Ap4b1-knockout mouse (SPG47 model): Motor dysfunction, aberrant brain morphology, and ATG9A mislocalization, providing mechanistic and preclinical-therapeutic validation for the AAV9-hAP4B1 gene-therapy program (PMC9825813). - Spg20−/− mouse (Troyer syndrome model): Reveals multimodal spartin functions in lipid-droplet maintenance, cytokinesis, and BMP signaling — expanding the mechanistic understanding of spartin beyond a single pathway (PMC3406757). - SPG50 preclinical AAV9/AP4M1 efficacy studies were conducted in a corresponding Ap4m1 mouse model prior to human dosing (PMC10178841).

Zebrafish models: - Spastizin (SPG15/ZFYVE26) zebrafish model: Shows axon demyelination and degeneration, extending the disease-relevant phenotype into a myelin-dysfunction axis not previously emphasized in mammalian models — a 2024 bioRxiv/PMC study (PMC11539067).

Cellular/iPSC and patient-derived models: - Patient-derived fibroblasts (SPG11, SPG15) show autophagosome accumulation and enlarged lysosomes, directly demonstrating defective autophagosome-lysosome fusion in a human cellular context (PMC4078876). - iPSC-derived neuronal models comparing SPG7 vs. SPAST patient-derived stem cells show that mitochondrial functional deficits are specific to SPG7, not SPAST, patient cells — an important cross-genotype mechanistic distinction (title: "Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells") (PMC7469654). - Patient-derived fibroblasts were also used directly for translational validation of AAV2/AP4M1 gene-therapy vectors prior to the human SPG50 trial (phenotypic rescue demonstrated in vitro).

Model limitations: Mouse Spg7 and Ap4b1 knockouts recapitulate core motor/axonal-degeneration phenotypes reasonably well, but full complex-HSP multisystem features (e.g., human-specific cognitive/retinal phenotypes in SPG11/15) are less completely captured in rodent models — this is consistent with the general caveat that mouse CNS models often under-represent human-specific cortical/cognitive phenotypes. Zebrafish models add a demyelination phenotype not otherwise emphasized in mouse data, suggesting species-dependent phenotypic emphasis.

Applications: These models have been directly used for (a) mechanistic dissection of the axonal-transport/ER/mitochondrial/lysosomal/autophagy pathways described in Section 6, and (b) as the essential preclinical efficacy/safety platform for the AAV gene-therapy programs now in human trials for SPG47 and SPG50.

Summary Table: Suggested Ontology Terms for KB Curation

Sources

• Genetic and phenotypic characterization of complex hereditary spastic paraplegia (PMC4939695)
• Insights into Clinical, Genetic, and Pathological Aspects of HSP: A Comprehensive Overview (PMC8662366)
• A complex form of HSP harboring p.W1515* in SPG11 (PMC8749458)
• Hereditary Spastic Paraplegia: An Update (PMC8835766)
• AP-4-Associated HSP – GeneReviews (NBK535153)
• Uncomplicated (Pure) HSP Overview – GeneReviews (NBK1509)
• Spastic Paraplegia 11 – GeneReviews (NBK1210)
• Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery (PMC8004882)
• Ascending Axonal Degeneration of the Corticospinal Tract in Pure HSP: DTI Study (PMC6827077)
• Impaired lipid metabolism in astrocytes underlies degeneration of cortical projection neurons in HSP (PMC7720406)
• Axon demyelination and degeneration in a zebrafish spastizin model of HSP (PMC11539067)
• Lysosomal abnormalities in HSP types SPG15 and SPG11 (PMC4078876)
• In Vivo Evidence for Lysosome Depletion and Impaired Autophagic Clearance in SPG11 (PMC4540459)
• Janus-faced spatacsin (SPG11), Brain 2020
• Impaired mitochondrial dynamics underlie axonal defects in HSP (PMC6031053)
• REEP1, spastin, atlastin-1 coordinate microtubule interactions with tubular ER network – PMID 20200447 / PMC2846052
• Global epidemiology of hereditary ataxia and spastic paraplegia – PMID 24603320
• An integrated modelling methodology for estimating global incidence/prevalence of SPG4/7/11/15 (PMC8944001)
• Epidemiology of HSP and mental health outcomes in England/N. Ireland (PMC12210554)
• Natural history in HSP: Austrian cohort, J Neurol 2025 (PMC12835074)
• Rapidly deteriorating course in Dutch SPG11 patients (PMC3798836)
• HSP type 5: natural history, biomarkers, RCT – PMID 29126212
• Cure AP-4 / Cure SPG47 Foundation
• Pre-clinical AP4B1 gene replacement therapy for SPG47 (PMC11554807)
• Intrathecal AAV9/AP4M1 gene therapy for SPG50, preclinical (PMC10178841)
• AAV gene therapy for HSP type 50: phase 1 single-patient trial, Nature Medicine (PMC11271397)
• Elpida Therapeutics Phase III SPG50 trial announcement
• SPG50 Gene Therapy Warrants Further Study (CGTlive)
• The Neuro-Ophthalmologic Manifestations of SPG7-Associated Disease (PMC12565430)
• Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia (eBioMedicine)
• Mitochondrial Function in HSP: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells (PMC7469654)
• Ap4b1-knockout mouse model of SPG47 (PMC9825813)
• Elevated hydroxycholesterols in Norwegian SPG5 patients
• Sequence alterations within CYP7B1 – PMID 18252231
• AAV8-based gene replacement therapy for HSP type 5 (PMC12309954)
• mRNA as a Novel Treatment Strategy for HSP Type 5 (Cell.com)
• Mutation of FA2H underlies SPG35 – PMID 20104589
• HSP type 35 with novel FA2H mutation, literature review (PMC6238570)
• SPG20/Spartin – Wikipedia synthesis
• Spg20−/− mice reveal multimodal functions for spartin (PMC3406757)
• Clinical-Genetic Features Influencing Disability in SPG4 (Neurology Genetics)
• Children with suspected HSP benefit from whole exome analysis (Human Genomics, Springer)
• Exome sequencing diagnostic tool for complicated HSP – PMID 23438842
• Non-pharmacological treatment of HSP: systematic review (PMC10858081)
• Botulinum Toxin Treatment in HSP — Comprehensive Review (PMC12567745)
• Efficacy of combined botulinum toxin + intensive physiotherapy in HSP (PMC7046620)
• The Puzzle of HSP: From Epidemiology to Treatment (PMC9321931)
• Lipids in the Physiopathology of HSPs (PMC7059351)
• Pharos: complex hereditary spastic paraplegia disease page
• OMIM #182600 SPG3A, OMIM #270800 SPG5A, OMIM #604805 SPG12